Conference Coverage

VIDEO: Researchers closing in on the elusive ‘male pill’


 

REPORTING FROM ENDO 2018

Some men reported a drop in libido that resolved by the end of the study. There was also mild weight gain and small reductions in HDL cholesterol. A few tweaks to the formulation or dosing might fix those problems. “Overall, we were very encouraged about the safety profile,” Dr. Page said.

Robert Lodge

Dr. Stephanie Page Stills

She explained the work, its promise, and the next steps in a video interview at the Endocrine Society’s annual meeting. The National Institutes of Health is funding development. Dr. Page didn’t have any relevant disclosures.

SOURCE: Page S et al. ENDO 2018, Abstract OR15-2.

Pages

Recommended Reading

ADT not associated with increased risk of dementia in larger study
MDedge Endocrinology
New PAD guidelines expected to boost awareness and treatment
MDedge Endocrinology
Clinicians underusing statins, aspirin in HIV patients
MDedge Endocrinology
Testosterone Trials’ cardiac, cognitive results disappoint
MDedge Endocrinology
Ask patients about sexual function at first visit
MDedge Endocrinology
VIDEO: Low testosterone common after testicular cancer
MDedge Endocrinology
Hypogonadism after testicular cancer treatment can have lifelong impact
MDedge Endocrinology
Meta-analysis shows correlation between diabetes and erectile dysfunction
MDedge Endocrinology
Free testosterone linked to frailty in older men
MDedge Endocrinology
Without reliability, testosterone testing may fall short
MDedge Endocrinology